Photo taken from Jun Gong/X
Jun 7, 2024, 06:44
Jun Gong: Dr. Fang PhI trial hypoxia-responsive CEA CAR-T in refractory solid tumors
Jun Gong, Medical oncologist and researcher in gastrointestinal and genitourinary cancers at Cedars-Sinai, shared a post on X:
“Dr. Fang PhI trial hypoxia-responsive CEA CAR-T in refractory solid tumors (35/40 #mCRC pts) enrolled to IV or IP administration depending on predominant peritoneal Mets. IP ORR 25% vs 8% IV, 100% G3-4 heme toxicity, G1-2 CRS 62.5% all patients.”
Source: Jun Gong/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 22, 2024, 05:05
Dec 22, 2024, 04:53
Dec 22, 2024, 04:52
Dec 22, 2024, 04:49